Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research.

Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research.

Item

http://www.wikidata.org/entity/Q34581504

Q34581504

about

Second-line treatment of metastatic gastric cancer: Current options and future directions State of the art management of metastatic gastroesophageal cancer Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis Phase II Study of Adjuvant Chemoradiotherapy Using Docetaxel/Cisplatin/5-Fluorouracil Before and After Intensity-modulated Radiotherapy With Concurrent Docetaxel in Patients With Completely (R0) Resected Gastric Carcinoma.Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.A phase II trial of paclitaxel, 5-fluorouracil (5-FU) and cisplatin in patients with metastatic or recurrent gastric cancer.Docetaxel combined with oral etoposide as second-line treatment for advanced gastric carcinoma after failure of platinum- and fluoropyrimidine-based regimens.Bimonthly regimen of high-dose leucovorin, infusional 5-fluorouracil, docetaxel, and cisplatin (modified DCF) in advanced gastric adenocarcinoma.Efficacy and tolerability of chemotherapy with modified dose-dense TCF regimen (TCF-dd) in locally advanced or metastatic gastric cancer: final results of a phase II trial.Histological complete response to a combined docetaxel/cisplatin/fluorouracil neoadjuvant chemotherapy for T4 stage gastric adenocarcinoma.Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial.Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer.Efficacy and safety of taxane-based systemic chemotherapy of advanced gastric cancer: A systematic review and meta-analysis.Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.A phase II study of weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction.Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis Cisplatin or not in advanced gastric cancer: a systematic review and meta-analysis.Incidence, time course and independent risk factors for metachronous peritoneal carcinomatosis of gastric origin--a longitudinal experience from a prospectively collected database of 1108 patients.Refining docetaxel-containing therapy for gastric cancer.GTSE1 expression represses apoptotic signaling and confers cisplatin resistance in gastric cancer cells.Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807).Comparative analysis of the efficacy and safety of modified FOLFOX-6 and DCF regimens as first-line treatment in advanced gastric cancer.A pilot study evaluating the safety and toxicity of epirubicin, cisplatin, and UFT (ECU regimen) in advanced gastric carcinoma The role of taxanes in the management of gastroesphageal cancer Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction foll Blockade of VEGFR-1 and VEGFR-2 enhances paclitaxel sensitivity in gastric cancer cells.Review of docetaxel in the treatment of gastric cancer.Global perspectives on chemotherapy for patients with gastric carcinoma: a roundtable discussion.Current status and future of chemotherapy and biochemotherapy in gastroesophageal cancers.Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114).Upper gastrointestinal tumors: current status and future perspectives.Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis Phase II study of docetaxel, cisplatin and capecitabine as preoperative chemotherapy in resectable gastric cancer.Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study).The BC Cancer Agency Compassionate Access Program: outcome analysis of patients with esophagogastric cancer.Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START).Systemic therapy for advanced gastric cancer: a clinical practice guideline.

P2860

Q26778027-FB5D6854-D117-4DF6-AEE8-4C38A537C7AA Q26779217-D9BE82BA-D924-4D1D-806F-A072C432DF27 Q26798400-E1DA9714-0C66-4605-B3ED-251C08244416 Q30491067-90333A5D-5C31-4FE4-B016-66BB20977F9A Q33380002-50CAD37F-8403-4D5E-95E6-D58506048171 Q33385867-37AEDADD-CC85-4A68-92A5-272ED38A672F Q33386661-597BEDCB-E7AF-40C7-A39A-F922395DC6AB Q33403949-CD3E0F37-6191-4D61-BABD-31DED6842A0D Q33411751-4CC2FC92-28FA-42BC-84B5-9EF3777F75B5 Q33657791-9E20A441-2AED-4590-A3B6-92F759491B33 Q33658659-4435AC9D-DFA8-4C00-BD45-4D2CEFB7CA80 Q33672879-283B8CCE-F105-4A2C-8ED5-A3C470999B96 Q33902814-AE1336C1-3EA1-4EB8-8E09-7BFCAD407590 Q33942343-8277EB2C-C7B9-40CA-9782-AB7820C1AAB7 Q33990928-123F25A0-FBCA-45EC-925C-A8761075C2E4 Q34344182-44283683-0628-46AF-BF9C-86FD359E26E7 Q34594956-070903FA-8F35-40E3-8278-8DD00F7B1702 Q34609932-C47055F5-9773-4A65-8B07-90FC980036BC Q34672942-D611AED7-DFAC-49E2-9422-1C493009FEFF Q35080136-4B33EC20-6289-4C5B-B77F-C9424C78CE7C Q35110064-EBBD9EBB-A562-4B44-A7C5-CBB3ED2E9AFD Q35445166-DE89E792-D45E-474B-8C8A-38ADF0F74EB1 Q35712961-D094A2F1-9488-4F65-8342-3319817DF810 Q35713647-2D34B4EE-1EC7-4A64-961B-5DDCE7234D0F Q35948108-7AFB2BD6-485B-4F46-9D20-93D6A36390DB Q36097126-C4319603-BAD9-44DD-8790-3B6A4C5616ED Q36097240-D3835EC5-6D3E-492D-9DEB-33E4F1A05883 Q36516605-4E6D3DB6-A929-426D-AC54-10E95DEA8430 Q36620293-76839003-4602-4690-A601-832033E948E4 Q37052880-2E9EC2CA-ABAB-49EF-B479-9A2BF5A44685 Q37077212-38763FD4-4E84-4118-ACFD-05EB22A6A752 Q37077239-4258D195-F045-4F8B-A839-19AC4A1FF318 Q37160119-FD637F99-401C-4E5D-8538-DA3F4EDB7619 Q37183479-550C3995-D8C4-4328-BC3C-F9A85132C13A Q37197679-8323B2AB-91B0-4716-A03C-D3190EFF657E Q37369163-674B818E-FF00-476B-8CFD-D6D2F6F78DDB Q37401491-2A8A9C99-992C-4D1C-8B39-83EDCBD0A915 Q37401643-E1833DEB-FC58-43D5-8D04-4B440E6E99B4 Q37491365-939C33B9-3EF3-43F0-BD4F-89AF88D6A667 Q37923311-28C221E4-8B05-47EE-9B88-399771AFDD7D

P2860

Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research.

Item

http://www.wikidata.org/entity/Q34581504

description

2007 nî lūn-bûn

@nan

2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu